Sensei Biotherapeutics Management
Management criteria checks 3/4
Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.92 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $32.19K. The average tenure of the management team and the board of directors is 2.1 years and 4 years respectively.
Key information
John Celebi
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 52.6% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$30m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$1m | US$532k | -US$34m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$513k | -US$49m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$7m | US$487k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$2m | US$395k | -US$20m |
Compensation vs Market: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Celebi (52 yo)
6.9yrs
Tenure
US$1,012,289
Compensation
Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$1.01m | 0.25% $ 32.2k | |
| Chief Scientific Officer | 2.1yrs | US$739.08k | 0.14% $ 18.3k | |
| Senior VP of Finance | less than a year | no data | no data | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| Senior VP | 2.5yrs | no data | no data | |
| Chief Business Officer | 1.2yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
2.1yrs
Average Tenure
50yo
Average Age
Experienced Management: SNSE's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$1.01m | 0.25% $ 32.2k | |
| Independent Director | 9.1yrs | US$75.56k | 1.35% $ 174.8k | |
| Independent Chairman | 2.8yrs | US$101.57k | 0.063% $ 8.2k | |
| Independent Director | 8yrs | US$73.39k | 0.084% $ 10.9k | |
| Member of Immuno-Oncology Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 4yrs | US$69.32k | 0.018% $ 2.3k | |
| Independent Director | 5yrs | US$68.43k | no data | |
| Member of Immuno-Oncology Advisory Board | no data | no data | no data | |
| Member of Immuno-Oncology Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 3.5yrs | US$62.24k | 0.018% $ 2.3k | |
| Member of Immuno-Oncology Advisory Board | no data | no data | no data | |
| Member of Immuno-Oncology Advisory Board | no data | no data | no data |
4.0yrs
Average Tenure
60yo
Average Age
Experienced Board: SNSE's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 22:18 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sensei Biotherapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Samantha Lynn Semenkow | Citigroup Inc |
| Edward White | H.C. Wainwright & Co. |